Genetically determined polymorphisms in drug oxidation

[1]  R. Branch,et al.  Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co‐regulated substrate, mephobarbital , 1986, Clinical pharmacology and therapeutics.

[2]  W. Kalow.  Genetics of drug transformation. , 1986, Clinical biochemistry.

[3]  L. Bertilsson,et al.  Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers , 1986, Clinical pharmacology and therapeutics.

[4]  T. Shimada,et al.  Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. , 1986, The Journal of biological chemistry.

[5]  G. Tucker,et al.  The Polymorphic Oxidation of β-Adrenoceptor Antagonists , 1986 .

[6]  G. Tucker,et al.  Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. , 1985, British journal of clinical pharmacology.

[7]  J. Bircher,et al.  Polymorphic dextromethorphan metabolism: Co‐segregation of oxidative O‐demethylation with debrisoquin hydroxylation , 1985, Clinical pharmacology and therapeutics.

[8]  W. Kalow,et al.  Mephenytoin hydroxylase activity in human liver: inhibition by steroids. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[9]  T. Kronbach,et al.  Mephenytoin hydroxylation polymorphism: Characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo , 1985, Clinical pharmacology and therapeutics.

[10]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[11]  J. J. Fleming,et al.  Pharmacokinetics and beta‐blocking effects of timolol in poor and extensive metabolizers of debrisoquin , 1985, Clinical pharmacology and therapeutics.

[12]  J. Lindsten,et al.  A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin , 1985, Clinical pharmacology and therapeutics.

[13]  B. Tang,et al.  N-Glucosidation of amobarbital in the cat. , 1985, Canadian journal of physiology and pharmacology.

[14]  R. Branch,et al.  Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation , 1985, Clinical pharmacology and therapeutics.

[15]  R. Branch,et al.  Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. , 1985, The Journal of pharmacology and experimental therapeutics.

[16]  G McKay,et al.  Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin , 1985, Clinical pharmacology and therapeutics.

[17]  F. Guengerich,et al.  Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. , 1985, The Journal of biological chemistry.

[18]  W. Kalow,et al.  In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[19]  M. Brodie,et al.  Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine? , 1985, British journal of clinical pharmacology.

[20]  M. Eichelbaum,et al.  Dissociation of co‐regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians , 1985, Clinical pharmacology and therapeutics.

[21]  W. Kalow,et al.  Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians. , 1985, British journal of clinical pharmacology.

[22]  G. Tucker,et al.  Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. , 1985, British journal of clinical pharmacology.

[23]  A. Boobis,et al.  Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities. , 1985, Biochemical pharmacology.

[24]  G. Wilkinson,et al.  Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism , 1984, Clinical pharmacology and therapeutics.

[25]  M. Danhof,et al.  Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. , 1984, Biochemical pharmacology.

[26]  M. Hetzel,et al.  Metabolic oxidation phenotypes as markers for susceptibility to lung cancer , 1984, Nature.

[27]  B. Mellström,et al.  Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes , 1984, Clinical pharmacology and therapeutics.

[28]  C. S. Haley,et al.  Genetic aspects of the polymodally distributed sulphoxidation of S-carboxymethyl-L-cysteine in man. , 1984, British journal of clinical pharmacology.

[29]  E. Vesell.  Pharmacogenetic Perspectives: Genes, Drugs and Disease , 1984, Hepatology.

[30]  L. Ramsay,et al.  Quantification of side-effects of beta-adrenoceptor blockers using visual analogue scales. , 1984, British journal of clinical pharmacology.

[31]  R. Branch,et al.  Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans. , 1984, The Journal of pharmacology and experimental therapeutics.

[32]  G. Wilkinson,et al.  Polymorphic ability to metabolize propranolol alters 4‐hydroxypropranolol levels but not beta blockade , 1984, Clinical pharmacology and therapeutics.

[33]  F. Guengerich,et al.  Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. , 1984, Biochemistry.

[34]  L. Bertilsson,et al.  Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism , 1984, Clinical pharmacology and therapeutics.

[35]  R T Schimke,et al.  Gene amplification, drug resistance, and cancer. , 1984, Cancer research.

[36]  G. Tucker,et al.  Protecting the poor metaboliser—from Jack & Wilkins. Dr Lennard et al. reply as follows , 1984 .

[37]  O. Hankinson,et al.  The Ah receptor: binding specificity only for foreign chemicals? , 1984, Biochemical pharmacology.

[38]  W. Kalow,et al.  Sparteine oxidation by the human liver: Absence of inhibition by mephenytoin , 1984, Clinical pharmacology and therapeutics.

[39]  K. Okumura,et al.  Quinidine‐induced rise in ajmaline plasma concentration , 1984, The Journal of pharmacy and pharmacology.

[40]  W. Kalow,et al.  Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. , 1984, Life sciences.

[41]  R. Branch,et al.  Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. , 1984, Journal of chromatography.

[42]  P. Beaune,et al.  Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. , 1983, Biochemistry.

[43]  A. Ashworth,et al.  Factors controlling the expression of genes coding for drug-metabolizing enzymes. , 1983, Biochemical Society Transactions.

[44]  B. Tang,et al.  Variation in amobarbital metabolism: Evaluation of a simplified population study , 1983, Clinical pharmacology and therapeutics.

[45]  M. Penno,et al.  Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation. , 1983, The Journal of clinical investigation.

[46]  G. Pfaff,et al.  Inter-individual variation in the metabolism of dextromethorphan , 1983 .

[47]  J. Idle,et al.  Genetically determined oxidation capacity and the disposition of debrisoquine. , 1983, British journal of clinical pharmacology.

[48]  L. Bertilsson,et al.  Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. , 1983, British journal of clinical pharmacology.

[49]  W. Kalow,et al.  Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. , 1983, Life sciences.

[50]  G. Tucker,et al.  Oxidation phenotype--a major determinant of metoprolol metabolism and response. , 1982, The New England journal of medicine.

[51]  F. Guengerich,et al.  Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone. , 1982, Biochemistry.

[52]  M. Eichelbaum,et al.  Application of Stable Labelled Drugs in Clinical Pharmacokinetic Investigations , 1982, Clinical pharmacokinetics.

[53]  J. Idle,et al.  Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains. , 1982, Biochemical pharmacology.

[54]  W. Kalow,et al.  Ethnic Differences in Drug Metabolism , 1982, Clinical pharmacokinetics.

[55]  M. Lennard,et al.  Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. , 1982, British journal of clinical pharmacology.

[56]  D. Nebert,et al.  Multiple forms of cytochrome P-450 and the importance of molecular biology and evolution. , 1982, Biochemical pharmacology.

[57]  R. Branch,et al.  Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man. , 1982, The Journal of pharmacology and experimental therapeutics.

[58]  G. Alván,et al.  HIGH PLASMA CONCENTRATIONS OF β-RECEPTOR BLOCKING DRUGS AND DEFICIENT DEBRISOQUINE HYDROXYLATION , 1982, The Lancet.

[59]  L. Bertilsson,et al.  Metabolism of various drugs in subjects with different debrisoquine and sparteine oxidation phenotypes , 1982 .

[60]  L. Bertilsson,et al.  Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities , 1982, Clinical pharmacology and therapeutics.

[61]  J. Idle,et al.  Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. , 1982, British medical journal.

[62]  W. Kalow,et al.  Sparteine metabolism in Canadian Caucasians , 1982, Clinical pharmacology and therapeutics.

[63]  Y. T. Chen,et al.  Cytochrome P1-450 structural gene in mouse, rat, and rabbit: differences in DNA methylation and developmental expression of mRNA. , 1982, DNA.

[64]  W. Kalow,et al.  In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine. , 1982, Canadian journal of physiology and pharmacology.

[65]  M. O. Dayhoff,et al.  Nucleic acid sequence database IV. , 1982, DNA.

[66]  M. Eichelbaum.  Defective Oxidation of Drugs: Pharmacokinetic and Therapeutic Implications , 1982, Clinical pharmacokinetics.

[67]  J. Idle,et al.  Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strains , 1981, The Journal of pharmacy and pharmacology.

[68]  L. Bertilsson,et al.  E‐ and Z‐10‐hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation , 1981, Clinical pharmacology and therapeutics.

[69]  R. Branch,et al.  Stereoselective metabolism of mephenytoin in man. , 1981, The Journal of pharmacology and experimental therapeutics.

[70]  J. Idle,et al.  Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation , 1981, Clinical pharmacology and therapeutics.

[71]  W. Kalow,et al.  Debrisoquine hydroxylation capacity: Problems of assessment in two populations , 1981, Clinical pharmacology and therapeutics.

[72]  M. Brodie,et al.  Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. , 1981, British journal of clinical pharmacology.

[73]  M. Danhof,et al.  Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation. , 1981, Pharmacology.

[74]  J. Idle,et al.  The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population. , 1980, Xenobiotica; the fate of foreign compounds in biological systems.

[75]  J. Idle,et al.  GENETIC IMPAIRMENT OF PHENFORMIN METABOLISM , 1980, The Lancet.

[76]  W. Kalow,et al.  Deficient metabolism of debrisoquine and sparteine , 1980, Clinical pharmacology and therapeutics.

[77]  J. Idle,et al.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. , 1980, Journal of medical genetics.

[78]  D. Daly,et al.  Inheritance of phenytoin hypometabolism: A kinetic study of one family , 1980, Clinical pharmacology and therapeutics.

[79]  J. Idle,et al.  Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians , 1979, Clinical pharmacology and therapeutics.

[80]  J. Idle,et al.  Genetic evidence for the involvement of different oxidative mechanisms in drug oxidation , 1979, The Journal of pharmacy and pharmacology.

[81]  J. Idle,et al.  Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. , 1979, Xenobiotica; the fate of foreign compounds in biological systems.

[82]  J. Idle,et al.  The metabolism of [14C]-debrisoquine in man. , 1979, British journal of clinical pharmacology.

[83]  J. Idle,et al.  Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. , 1979, Drug metabolism reviews.

[84]  J. Idle,et al.  A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians. , 1979, Xenobiotica; the fate of foreign compounds in biological systems.

[85]  J. Mucklow,et al.  Contribution of environmental factors to variability in human drug metabolism. , 1979, Drug metabolism reviews.

[86]  F. Guengerich,et al.  Isolation and purification of cytochrome P-450, and the existence of multiple forms. , 1979, Pharmacology & therapeutics.

[87]  B. Tang,et al.  Distinctive patterns of amobarbital metabolites , 1978, Clinical pharmacology and therapeutics.

[88]  J. Idle,et al.  Polymorphism of carbon oxidation of drugs and clinical implications. , 1978, British medical journal.

[89]  J. Idle,et al.  Hypotensive response to debrisoquine and hydroxylation phenotype. , 1978, Life sciences.

[90]  E. Vesell.  Genetic and environmental factors affecting drug disposition in man , 1977, Clinical pharmacology and therapeutics.

[91]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[92]  B. Tang,et al.  A case of deficiency of N‐hydroxylation of amobarbital , 1977, Clinical pharmacology and therapeutics.

[93]  G. Tucker,et al.  Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course. , 1977, British medical journal.

[94]  A. Y. Lu,et al.  Multiple forms of rat liver cytochrome P-450. Immunochemical evidence with antibody against cytochrome P-448. , 1976, The Journal of biological chemistry.

[95]  D. Herries.  Enzyme Kinetics: Behaviour and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems: By Irwin H. Segel. John Wiley & Sons, 1975. pp xxii + 957. Boards, £15.00 , 1976 .

[96]  Glynn Jp,et al.  Letter: paracetamol measurement. , 1975 .

[97]  W. Martin,et al.  Letter: Jaundice associated with norethisterone-acetate treatment of breast cancer. , 1975, Lancet.

[98]  N. Shahidi.  ACETOPHENETIDIN‐INDUCED METHEMOGLOBINEMIA * , 1968 .

[99]  F. Mcdowell,et al.  Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity , 1964, Neurology.

[100]  W. E. Gye.  WILLIAM Ewart Gye , 1952 .